Loading people...
David Parkinson is a Venture Partner at New Enterprise Associates and the President and CEO of ESSA Pharma, based in the San Francisco Bay Area. Before joining NEA in 2012, he held senior clinical leadership positions across the biopharmaceutical industry, including serving as Vice President of Oncology Development at Novartis and Vice President of Clinical Oncology at Amgen. He also previously worked as Chief Medical Officer at Biogen Idec and held roles at the National Cancer Institute, building a track record in oncology drug development. Parkinson serves on the boards of multiple biotechnology companies, notably acting as a director for CTI BioPharma until its $1.7 billion acquisition by Sobi in 2023. He leverages his medical training from the University of Toronto to guide early-stage life sciences investments and lead clinical-stage therapeutic ventures.
David Parkinson is a distinguished Venture Partner at New Enterprise Associates (NEA), one of the world's largest and most active venture capital firms. In his capacity, David plays a crucial role in supporting NEA's extensive portfolio, offering invaluable strategic advice, operational insights, and mentorship to founders and management teams. His contributions are instrumental in helping promising companies scale, innovate, and achieve market leadership.
NEA is renowned for its broad investment mandate, spanning technology, healthcare, and other high-growth industries. As a Venture Partner, David Parkinson's focus aligns with NEA's mission to back visionary entrepreneurs building transformative businesses. While specific investment areas can be diverse, his work often involves identifying companies with strong potential for disruption and sustainable growth, particularly those poised to benefit from strategic guidance in areas like market entry, product development, and operational efficiency. He helps bridge the gap between innovative ideas and successful execution, ensuring portfolio companies are well-equipped to navigate competitive landscapes.
David brings a wealth of experience to his role, drawing from a robust career background that has equipped him with a deep understanding of business dynamics and market trends. While specific details of his career trajectory prior to NEA are not publicly detailed, individuals in Venture Partner roles typically possess extensive operational experience, often having held senior leadership positions in successful companies or having founded and scaled their own ventures. This background allows David to offer practical, real-world advice, making him a trusted advisor to the entrepreneurs NEA supports. His expertise is leveraged across various stages of investment, from early-stage startups to more mature growth-stage companies.
At NEA, collaboration is key, and David Parkinson's efforts contribute significantly to the collective success of the firm's investments. While specific individual investments are often a collaborative effort across the NEA team, David's strategic input and guidance are integral to the development and growth of numerous portfolio companies. He is dedicated to fostering innovation and helping companies realize their full potential, reinforcing NEA's reputation as a leading partner for entrepreneurs worldwide. His work exemplifies NEA's commitment to not just providing capital, but also offering deep strategic and operational support to drive long-term value creation.
David Parkinson is a Venture Partner at New Enterprise Associates (NEA), a prominent global venture capital firm. He plays a key role in providing strategic guidance and operational support to NEA's portfolio companies.
As a Venture Partner at NEA, David Parkinson contributes to investments across a broad spectrum of sectors, consistent with NEA's focus on technology, healthcare, and other high-growth industries. His work involves identifying innovative companies and supporting their development.
David Parkinson works at New Enterprise Associates (NEA), one of the world's largest and most active venture capital firms, known for investing in companies at various stages from seed to growth.
